Literature DB >> 10037026

Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.

B A Witthuhn1, M D Williams, H Kerawalla, F M Uckun.   

Abstract

Substrate recognition by Janus family protein tyrosine kinases was examined utilizing recombinant baculovirus produced components of the interleukin 2 receptor (IL2R) system i.e. Jak1, Transducers and Activators of Transcription (STAT). Wild type Jak3 was able to tyrosine phosphorylate a kinase-dead Jak1 (Jak1E908). In contrast wild type Jak1 was unable to tyrosine phosphorylate kinase dead Jak3 (Jak3E851). This unilateral transphosphorylation between Jak3 and Jak1 prompts the hypothesis that in the IL2R system the activation of Jak3 precedes Jak1 activation. Both the IL2Rbeta and IL2Rgammac subunits underwent tyrosine phosphorylation when co-expressed with wild-type Jak3. By comparison only IL2Rbeta was recognized and tyrosine phosphorylated by wild-type Jak1. These results are consistent with the notion that Jakl is pre-associated with IL2Rbeta and Jak3 is pre-associated with IL2Rgammac. STAT1, STAT3, and STAT5 underwent tyrosine phosphorylation when co-expressed with Jakl and therefore are substrates for the respective Jak kinases. In contrast, Jak3 co-expression resulted in tyrosine phosphorylation of STAT3 and STAT5 but not STAT1. Notably a polypeptide representing the kinase domain of Jak3 (Jak3-JH1) gained the ability to tyrosine phosphorylate STAT1, suggesting that the changes in substrate recognition may be influenced by domains outside the kinase domain. These findings provide evidence that Jak1 and Jak3 differentially recognize specific substrates, thereby having the ability to contribute specific signals, and the substrate specificity may be influenced by multiple domains of these tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037026     DOI: 10.3109/10428199909167389

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation.

Authors:  Y J Zhou; K S Magnuson; T P Cheng; M Gadina; D M Frucht; J Galon; F Candotti; R L Geahlen; P S Changelian; J J O'Shea
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  The extracellular and transmembrane domains of the γC and interleukin (IL)-13 receptor α1 chains, not their cytoplasmic domains, dictate the nature of signaling responses to IL-4 and IL-13.

Authors:  Nicola M Heller; Xiulan Qi; Franck Gesbert; Achsah D Keegan
Journal:  J Biol Chem       Date:  2012-07-24       Impact factor: 5.157

Review 3.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 4.  Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?

Authors:  Przemysław J Kotyla; Małgorzata Engelmann; Joanna Giemza-Stokłosa; Bartosz Wnuk; Md Asiful Islam
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

5.  Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling.

Authors:  Geoffrey A Smith; Kenji Uchida; Arthur Weiss; Jack Taunton
Journal:  Nat Chem Biol       Date:  2016-03-28       Impact factor: 15.040

Review 6.  Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer.

Authors:  Arturo Valle-Mendiola; Adriana Gutiérrez-Hoya; María del Carmen Lagunas-Cruz; Benny Weiss-Steider; Isabel Soto-Cruz
Journal:  Mediators Inflamm       Date:  2016-05-12       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.